This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fasola, E.
Right arrow Articles by Appelbaum, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fasola, E.
Right arrow Articles by Appelbaum, P. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Nov 1996, 2661-2663, Vol 40, No. 11
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci

E Fasola, SK Spangler, LM Ednie, MR Jacobs, S Bajaksouzian and PC Appelbaum
Department of Pathology (Clinical Microbiology), Case Western Reserve University, Cleveland, Ohio 44106, USA.

Microdilution MIC testing was used to test the susceptibility of 202 pneumococci to LY 333328 and six other agents. LY 333328 was the most active glycopeptide (MIC at which 90% of the pneumococci were inhibited [MIC90], 0.008 microgram/ml), followed by teicoplanin (MIC90, 0.06 microgram/ml) and vancomycin (MIC90, 0.5 microgram/ml). Rifampin resistance was seen in some penicillin-resistant strains. The MICs of imipenem and ceftriaxone rose with those of penicillin. Time-kill testing confirmed the excellent antipneumococcal activity of LY 333328.


This article has been cited by other articles:

  • Attwood, R. J., LaPlante, K. L. (2007). Telavancin: A novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 2335-2348 [Abstract] [Full Text]  
  • Cabellos, C., Fernandez, A., Maiques, J. M., Tubau, F., Ardanuy, C., Viladrich, P. F., Linares, J., Gudiol, F. (2003). Experimental Study of LY333328 (Oritavancin), Alone and in Combination, in Therapy of Cephalosporin-Resistant Pneumococcal Meningitis. Antimicrob. Agents Chemother. 47: 1907-1911 [Abstract] [Full Text]  
  • Musher, D. M., Bartlett, J. G., Doern, G. V. (2001). A Fresh Look at the Definition of Susceptibility of Streptococcus pneumoniae to {beta}-Lactam Antibiotics. Arch Intern Med 161: 2538-2544 [Abstract] [Full Text]  
  • Gerber, J., Smirnov, A., Wellmer, A., Ragheb, J., Prange, J., Schutz, E., Wettich, K., Kalich, S., Nau, R. (2001). Activity of LY333328 in Experimental Meningitis Caused by a Streptococcus pneumoniae Strain Susceptible to Penicillin. Antimicrob. Agents Chemother. 45: 2169-2172 [Abstract] [Full Text]  
  • Zeckel, M. L., Preston, D. A., Allen, B. S. (2000). In Vitro Activities of LY333328 and Comparative Agents against Nosocomial Gram-Positive Pathogens Collected in a 1997 Global Surveillance Study. Antimicrob. Agents Chemother. 44: 1370-1374 [Abstract] [Full Text]  
  • Kaplan, S. L., Mason, E. O. Jr. (1998). Management of Infections Due to Antibiotic-Resistant Streptococcus pneumoniae. Clin. Microbiol. Rev. 11: 628-644 [Abstract] [Full Text]  
  • García-Garrote, F., Cercenado, E., Alcalá, L., Bouza, E. (1998). In Vitro Activity of the New Glycopeptide LY333328 against Multiply Resistant Gram-Positive Clinical Isolates. Antimicrob. Agents Chemother. 42: 2452-2455 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»